| Name | KRAS G12C inhibitor 5 |
|---|
| Description | KRAS G12C inhibitor 5 is a KRas G12C inhibitor extracted from patent WO2017201161A1, Compound example 147[1]. |
|---|---|
| Related Catalog | |
| Target |
KRas G12C[1] |
| In Vitro | Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (KRas) is a small GTPase and a member of the Ras family of oncogenes. KRas serves a molecular switch cycling between inactive (GDP -bound) and active (GTP -bound) states to transduce upstream cellular signals received from multiple tyrosine kinases to downstream effectors to regulate a wide variety of processes, including cellular proliferation[1]. |
| References |
[1]. John P. Fischer, et al. Kras g12c inhibitors. WO2017201161A1. |
| Molecular Formula | C32H37N7O2 |
|---|---|
| Molecular Weight | 551.68 |